NGF and Miyoshi myopathy: This polyclonal antibody-based technology identifies intact immunoglobulins at a higher sensitivity when compared to standard SPEP, with a moderate concordance with bone marrow NGF evaluation, thus offering a new way to detect MRD in peripheral blood for MM patients [48].